Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

19.50
-0.9800-4.79%
Post-market: 19.550.0500+0.26%19:15 EST
Volume:548.20K
Turnover:10.91M
Market Cap:988.11M
PE:33.60
High:20.60
Open:20.51
Low:19.35
Close:20.48
52wk High:21.03
52wk Low:7.90
Shares:50.67M
Float Shares:21.84M
Volume Ratio:1.22
T/O Rate:2.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5803
EPS(LYR):-1.1550
ROE:14.03%
ROA:-5.32%
PB:4.25
PE(LYR):-16.88

Loading ...

Theravance Biopharma: Asymmetric Upside from Ampreloxetine on Top of a Cash-Flow-Positive Base Business Supports Buy Rating

TIPRANKS
·
Feb 03

Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Theravance Biopharma (TBPH) and Align Tech (ALGN)

TIPRANKS
·
Feb 03

Theravance Biopharma Price Target Maintained With a $40.00/Share by BTIG

Dow Jones
·
Feb 03

Theravance Biopharma management to meet with B. Riley

TIPRANKS
·
Jan 23

mF International, Theravance Biopharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga_recent_news
·
Jan 05

Theravance Biopharma SVP Rhonda Farnum Sells Common Shares

Reuters
·
Dec 06, 2025

Theravance Biopharma Initiated at Outperform by Oppenheimer

Dow Jones
·
Dec 04, 2025

Theravance Biopharma Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $27

THOMSON REUTERS
·
Dec 03, 2025

Oppenheimer Initiates Theravance Biopharma at Outperform With $27 Price Target

MT Newswires Live
·
Dec 03, 2025

Theravance Biopharma Director Eran Broshy Reports Disposal of Common Shares

Reuters
·
Dec 02, 2025

Theravance Biopharma Is Maintained at Buy by BTIG

Dow Jones
·
Nov 26, 2025

Theravance Biopharma Hosts Virtual KOL Investor Event on Ampreloxetine Phase 3 Program

Reuters
·
Nov 21, 2025

Theravance Biopharma Q3 Operating Income USD -6.455 Million

Reuters
·
Nov 20, 2025

Theravance Biopharma management to meet virtually with BTIG

TIPRANKS
·
Nov 18, 2025

EXCLUSIVE-Activist investor Irenic builds stake in Papa John's, sources say

Reuters
·
Nov 15, 2025

Director Eran Broshy Sells Common Shares of Theravance Biopharma Inc

Reuters
·
Nov 14, 2025

Stock Track | Theravance Biopharma Soars 5.17% Following Strong Q3 Results and Analyst Upgrades

Stock Track
·
Nov 11, 2025

Stock Track | Theravance Biopharma Soars 5.17% on Strong Q3 Results and Analyst Upgrades

Stock Track
·
Nov 11, 2025

Theravance Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 11, 2025

Theravance Biopharma price target raised to $20 from $15 at H.C. Wainwright

TIPRANKS
·
Nov 11, 2025